A comprehensive review on combretastatin analogues as tubulin binding agents

Current Organic Chemistry

Volumn 18, Issue 19, 2014, Pages 2462-2512

  Gill, Rupinder K ^a,b   Kaur, Ramandeep ^a   Kaur, Gurneet ^a   Rawal, Ravindra K ^a   Shah, Anamik K ^c   Bariwal, Jitender ^a,b  

^a ISF COLLEGE OF PHARMACY   (India)

^b I K GUJRAL PUNJAB TECHNICAL UNIVERSITY   (India)

^c SAURASHTRA UNIVERSITY   (India)

Author keywords

Anticancer; Antiproliferative; Combretastatin; Combretastatin analogues; Microtubule binding agents; Tubulin binding agents

Indexed keywords

POLYMERIZATION; SYNTHESIS (CHEMICAL); SYNTHETIC APERTURE RADAR;

ANTI-PROLIFERATIVE; ANTICANCER; BINDING AGENT; COMBRETASTATIN; COMBRETASTATIN ANALOG; MICROTUBULE BINDING AGENT; MICROTUBULES; TUBULIN BINDING AGENT; TUBULIN POLYMERIZATION;

CHEMOTHERAPY;

EID: 84925867242     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/138527281819141028114428     Document Type: Article

References (70)

1. [1] Hartwell, L.H., Weinert, T.A. Checkpoints: Controls that ensure the order of cell cycle events. Science, 1989, 246(4930), 629-634.
2. [2] White, E. Life, death, and the pursuit of apoptosis. Genes Dev., 1996, 10(1), 1-15.
3. [3] Sampath, D., Plunkett, W. Design of new anticancer therapies targeting cell cycle checkpoint pathways. Curr. Opin. Oncol., 2001, 13(6), 484-490.
4. [4] Fojo, T., Giannakakou, P. Taxol and other microtubule-interactive agents. Curr. Opin. Oncolog. Endocr. Metabol. Investig. Drugs, 2000, 2, 293-304.
5. [5] McIntosh, J.R., Grishchuk, E.L., West, R.R. Chromosome-microtubule interactions during mitosis. Annu. Rev. Cell Dev. Biol., 2002, 18(1), 193-219.
6. [6] Jordan, M.A., Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4(4), 253-265.
7. [7] https://wikispaces.psu.edu/pages/viewpage.action?pageId=112525445&navigatingVersions=true (Acessed on 10-03-2014).
8. [8] Tron, G.C., Pirali, T., Sorba, G., Pagliai, F., Busacca, S., Genazzani, A.A. Medicinal chemistry of combretastatin A4: Present and future directions. J. Med. Chem., 2006, 49(11), 3033-3044.
9. [9] Shan, Y., Zhang J., Liu, Z., Wang, M., Dong, Y. Developments of combretastatin A-4 derivatives as anticancer agents. Curr. Med. Chem., 2011, 18(4), 523-538.
10. [10] Chaudhary, A., Pandeya S.N., Kumar, P., Sharma P.P., Gupta, S., Soni, N., Verma, K.K., Bhardwaj, G. Combretastatin-A4 analogs as anticancer agents. Mini Rev. Med. Chem., 2007, 7(12), 1186-1205.
11. [11] Rajak, H., Dewangan, P.K., Patel, V., Jain D.K., Singh, A., Veerasamy, R., Sharma, P.C., Dixit, A. Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers. Curr. Pharm. Des., 2013, 19(10), 1923-1955.
12. [12] Lu, Y., Chen, J., Xiao, M., Li, W., Miller, D.D. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm. Res., 2012, 29, 2943-2971.
13. [13] Angerer, E.V. New inhibitors of Tubulin polymerisation. Exp. Opin. Ther. Patents, 1999, 9(8), 1069-1081.
14. [14] Kiselyov, A., Balakin, K.V., Tkachenko, S.E., Savchuk, N., Ivachtchenko, A.V. Recent progress in discovery and development of antimitotic agents. Anti-Cancer Agents Med. Chem., 2007, 7, 189-208.
15. [15] Chen, J., Liu, T., Dong, X., Hu, Y. Recent development and SAR analysis of colchicine binding site inhibitors. Mini Rev. Med. Chem., 2009, 9, 1174-1190.
16. [16] Marrelli, M., Conforti, F., Statti, G.A., Cachet, X., Michel, S., Tillequin, F., Menichini, F. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin A-4. Curr. Med. Chem., 2011, 18(20), 3035-3081.
17. [17] Pettit, G.R., Cragg, G.M., Herald, D.L., Schmidt, J.M., Lohavanijaya, P. Isolation and structure of combretastatin. Can. J. Chem., 1982, 60(11), 1374-1376.
18. [18] Cushman, M., Nagarathnam, D., Gopal, D., He, H.M., Lin, C.M., Hamel, E. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3, 4, 5-trimethoxyphenyl) ethene as potential cytotoxic and antimitotic agents. J. Med. Chem., 1992, 35(12), 2293-2306.
19. [19] Chaudhary, A., Pandeya, S., Kumar, P., Sharma, P., Gupta, S., Soni, N., Verma, K., Bhardwaj, G. Combretastatin A-4 analogues as anticancer agents. Mini-Rev. Med. Chem., 2007, 7(12), 1186-1205.
20. [20] Pettit, G.R., Lippert, J. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des., 2000, 15(3), 203-216.
21. [21] Fürst, R., Zupkó, I., Berényi, Á., Ecker, G.F., Rinner, U. Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogues. Bioorg. Med. Chem. Lett., 2009, 19(24), 6948-6951.
22. [22] Diaz, J.F., Andreu, J.M. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry, 1993, 32(11), 2747-2755.
23. [23] Shepherd, F.A., Fossella, F.V., Lynch, T., Armand, J.P., Rigas, J.R., Kris, M.G. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials. Semin. Oncol., 2001, 28, 4-9.
24. [24] Chen, H., Li, Y., Sheng, C., Lv, Z., Dong, G., Wang, T., Liu, J., Zhang, M., Li, L., Zhang, T. Design and synthesis of cyclopropylamide analogues of combretastatin-A4 as novel microtubule-stabilizing agents. J. Med. Chem., 2013, 56(3), 685-699.
25. [25] Ty, N., Kaffy, J., Arrault, A., Thoret, S., Pontikis, R., Dubois, J., Morin-Allory, L., Florent, J.C. Synthesis and biological evaluation of cis-locked vinylogous combretastatin-A4 analogues: Derivatives with a cyclopropylvinyl or a cyclopropyl-amide bridge. Bioorg. Med. Chem. Lett., 2009, 19(5), 1318-1322.
26. [26] Carr, M., Greene, L.M., Knox, A.J., Lloyd, D.G., Zisterer, D.M., Meegan, M.J. Lead identification of conformationally restricted _-lactam type combretastatin analogues: Synthesis, antiproliferative activity and tubulin targeting effects. Eur. J. Med. Chem., 2010, 45(12), 5752-5766.
27. [27] Sun, L., Vasilevich, N.I., Fuselier, J.A., Hocart, S.J., Coy, D.H. Examination of the 1, 4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg. Med. Chem. Lett., 2004, 14(9), 2041-2046.
28. [28] Tripodi, F., Pagliarin, R., Fumagalli, G., Bigi, A., Fusi, P., Orsini, F., Frattini, M., Coccetti, P. Synthesis and biological evaluation of 1, 4-Diaryl-2-azetidinones as specific anticancer agents: activation of adenosine monophosphate activated protein kinase and induction of apoptosis. J. Med. Chem., 2012, 55(5), 2112-2124.
29. [29] O’Boyle, N.M., Carr, M., Greene, L.M., Bergin, O., Nathwani, S.M., McCabe, T., Lloyd, D.G., Zisterer, D.M., Meegan, M.J. Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents. J. Med. Chem., 2010, 53(24), 8569-8584.
30. [30] Biersack, B., Zoldakova, M., Effenberger, K., Schobert, R. (Arene) Ru (II) complexes of epidermal growth factor receptor inhibiting tyrphostins with enhanced selectivity and cytotoxicity in cancer cells. Eur. J. Med. Chem., 2010, 45(5), 1972-1975.
31. [31] Romagnoli, R., Baraldi, P.G., Cruz-Lopez, O., Lopez Cara, C., Carrion, M.D., Brancale, A., Hamel, E., Chen, L., Bortolozzi, R., Basso, G. Synthesis and antitumor activity of 1, 5-disubstituted 1, 2, 4-triazoles as cis-restricted combretastatin analogues. J. Med. Chem., 2010, 53(10), 4248-4258.
32. [32] Akselsen, Ø.W., Odlo, K., Cheng, J.J., Maccari, G., Botta, M., Hansen, T.V. Synthesis, biological evaluation and molecular modeling of 1, 2, 3-triazole analogues of combretastatin A-1. Bioorg. Med. Chem., 2012, 20(1), 234-242.
33. [33] Romagnoli, R., Baraldi, P.G., Salvador, M.K., Preti, D., Aghazadeh Tabrizi, M., Brancale, A., Fu, X.H., Li, J., Zhang, S.Z., Hamel, E. Synthesis and evaluation of 1, 5-disubstituted tetrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative and antitumor activity. J. Med. Chem., 2011, 55(1), 475-488.
34. [34] Theeramunkong, S., Caldarelli, A., Massarotti, A., Aprile, S., Caprioglio, D., Zaninetti, R., Teruggi, A., Pirali, T., Grosa, G., Tron, G.C. Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues. J. Med. Chem., 2011, 54(14), 4977-4986.
35. [35] Romagnoli, R., Baraldi, P.G., Brancale, A., Ricci, A., Hamel, E., Bortolozzi, R., Basso, G., Viola, G. Convergent synthesis and biological evaluation of 2-amino-4-(3', 4', 5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents. J. Med. Chem., 2011, 54(14), 5144-5153.
36. [36] Romagnoli, R., Baraldi, P.G., Salvador, M.K., Camacho, M.E., Preti, D., Tabrizi, M.A., Bassetto, M., Brancale, A., Hamel, E., Bortolozzi, R. Synthesis and biological evaluation of 2-substituted-4-(3', 4', 5'-trimethoxyphenyl)-5-aryl thiazoles as anticancer agents. Bioorg. Med. Chem., 2012, 20(24), 7083-7094.
37. [37] Kiselyov, A.S., Semenova, M.N., Chernyshova, N.B., Leitao, A., Samet, A.V., Kislyi, K.A., Raihstat, M.M., Oprea, T., Lemcke, H., Lantow, M. Novel derivatives of 1, 3, 4-oxadiazoles are potent mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin embryo and cell culture assays. Eur. J. Med. Chem., 2010, 45(5), 1683-1697.
38. [38] Lee, L., Robb, L.M., Lee, M., Davis, R., Mackay, H., Chavda, S., Babu, B., O’Brien, E.L., Risinger, A.L., Mooberry, S.L. Design, synthesis, and biological evaluations of 2, 5-diaryl-2, 3-dihydro-1, 3, 4-oxadiazoline analogues of combretastatin-A4. J. Med. Chem., 2009, 53(1), 325-334.
39. [39] Das, B.C., Tang, X.Y., Rogler, P., Evans, T. Design and synthesis of 3, 5-disubstituted boron-containing 1, 2, 4-oxadiazoles as potential combretastatin A-4 (CA-4) analogues. Tetrahedron Lett., 2012, 53(31), 3947-3950.
40. [40] Chen, J., Wang, Z., Li, C.M., Lu, Y., Vaddady, P.K., Meibohm, B., Dalton, J.T., Miller, D.D., Li, W. Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J. Med. Chem., 2010, 53(20), 7414-7427.
41. [41] Li, Y.W., Liu, J., Liu, N., Shi, D., Zhou, X.T., Lv, J.G., Zhu, J., Zheng, C.H., Zhou, Y.J. Imidazolone-amide bridges and their effects on tubulin polymerization in cis-locked vinylogous combretastatin-A4 analogues: Synthesis and biological evaluation. Bioorg. Med. Chem., 2011, 19(11), 3579-3584.
42. [42] Lee, L., Davis, R., Vanderham, J., Hills, P., Mackay, H., Brown, T., Mooberry, S.L., Lee, M. 1, 2, 3, 4-Tetrahydro-2-thioxopyrimidine analogues of combretastatin-A4. Eur. J. Med. Chem., 2008, 43(9), 2011-2015.
43. [43] La Regina, G., Bai, R., Rensen, W., Coluccia, A., Piscitelli, F., Gatti, V., Bolognesi, A., Lavecchia, A., Granata, I., Porta, A. Design and synthesis of 2-heterocyclyl-3-arylthio-1 H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability. J. Med. Chem., 2011, 54(24), 8394-8406.
44. [44] La Regina, G., Bai, R., Rensen, W.M., Di Cesare, E., Coluccia, A., Piscitelli, F., Famiglini, V., Reggio, A., Nalli, M., Pelliccia, S. Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors. J. Med. Chem., 2012, 56(1), 123-149.
45. [45] De Martino, G., La Regina, G., Coluccia, A., Edler, M.C., Barbera, M.C., Brancale, A., Wilcox, E., Hamel, E., Artico, M., Silvestri, R. Arylthioindoles, potent inhibitors of tubulin polymerization. J. Med. Chem., 2004, 47(25), 6120-6123.
46. [46] Romagnoli, R., Baraldi, P.G., Kimatrai Salvador, M., Preti, D., Aghazadeh Tabrizi, M., Bassetto, M., Brancale, A., Hamel, E., Castagliuolo, I., Bortolozzi, R. Synthesis and biological evaluation of 2-(alkoxycarbonyl)-3-anilinobenzo [b] thiophenes and thieno [2, 3-b] pyridines as new potent anticancer agents. J. Med. Chem., 2013, 56(6), 2606-2618.
47. [47] Ty, N., Dupeyre, G., Chabot, G.G., Seguin, J., Quentin, L., Chiaroni, A., Tillequin, F., Scherman, D., Michel, S., Cachet, X. Structure-activity relationships of indole compounds derived from combretastatin A4: Synthesis and biological screening of 5-phenylpyrrolo [3, 4-a] carbazole-1, 3-diones as potential antivascular agents. Eur. J. Med. Chem., 2010, 45(9), 3726-3739.
48. [48] Flynn, B.L., Gill, G.S., Grobelny, D.W., Chaplin, J.H., Paul, D., Leske, A.F., Lavranos, T.C., Chalmers, D.K., Charman, S.A., Kostewicz, E. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3, 4, 5-trimethoxybenzoyl) benzo [b] furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J. Med. Chem., 2011, 54(17), 6014-6027.
49. [49] Lorion, M., Agouridas, V., Couture, A., Deniau, E., Grandclaudon, P. Synthesis and cytotoxic evaluation of cis-locked and constrained analogues of combretastatin and combretastatin A4. Tetrahedron Lett., 2010, 51(39), 5146-5149.
50. [50] Zhao, D.G., Chen, J., Du, Y.R., Ma, Y.Y., Chen, Y.X., Gao, K., Hu, B.R. Synthesis and structure-activity relationships of N-methyl-5, 6, 7-trimethoxylindoles as novel antimitotic and vascular disrupting agents. J. Med. Chem., 2013, 56(4), 1467-1477.
51. [51] Andreani, A., Granaiola, M., Locatelli, A., Morigi, R., Rambaldi, M., Varoli, L., Calonghi, N., Cappadone, C., Farruggia, G., Stefanelli, C. Substituted 3-(5-Imidazo [2, 1-b] thiazolylmethylene)-2-indolinones and analogues: Synthesis, cytotoxic activity, and study of the mechanism of action (1). J. Med. Chem., 2012, 55(5), 2078-2088.
52. [52] Tung, Y.S., Coumar, M.S., Wu, Y.S., Shiao, H.Y., Chang, J.Y., Liou, J.P., Shukla, P., Chang, C.W., Chang, C.Y., Kuo, C.C. Scaffold-hopping strategy: Synthesis and biological evaluation of 5, 6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents. J. Med. Chem., 2011, 54(8), 3076-3080.
53. [53] Liu, J., Zheng, C.H., Ren, X.H., Zhou, F., Li, W., Zhu, J., Lv, J.G., Zhou, Y.J. Synthesis and biological evaluation of 1-Benzylidene-3, 4-dihydronaphthalen-2-one as a new class of microtubule-targeting agents. J. Med. Chem., 2012, 55(12), 5720-5733.
54. [54] Ruchelman, A.L., Man, H.W., Chen, R., Liu, W., Lu, L., Cedzik, D., Zhang, L., Leisten, J., Collette, A., Narla, R.K. 1, 1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4. Bioorg. Med. Chem., 2011, 19(21), 6356-6374.
55. [55] Rasolofonjatovo, E., Provot, O., Hamze, A., Rodrigo, J., Bignon, J., Wdzieczak-Bakala, J., Desravines, D., Dubois, J., Brion, J.D., Alami, M. Conformationnally restricted naphthalene derivatives type< i> isocombretastatin A-4 and iso erianin analogues: Synthesis, cytotoxicity and antitubulin activity. Eur. J. Med. Chem., 2012, 52, 22-32.
56. [56] Nien, C.Y., Chen, Y.C., Kuo, C.C., Hsieh, H.P., Chang, C.Y., Wu, J.S., Wu, S.Y., Liou, J.P., Chang, J.Y. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J. Med. Chem., 2010, 53(5), 2309-2313.
57. [57] Lee, J., Kim, S.J., Choi, H., Kim, Y.H., Lim, I.T., Yang, H.-M., Lee, C.S., Kang, H.R., Ahn, S.K., Moon, S.K. Identification of CKD-516: A potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J. Med. Chem., 2010, 53(17), 6337-6354.
58. [58] Combes, S., Barbier, P., Douillard, S., McLeer-Florin, A., Bourgarel-Rey, V., Pierson, J.T., Fedorov, A.Y., Finet, J.P., Boutonnat, J., Peyrot, V. Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2. J. Med. Chem., 2011, 54(9), 3153-3162.
59. [59] Gangjee, A., Zhao, Y., Hamel, E., Westbrook, C., Mooberry, S.L. Synthesis and biological activities of (R)-and (S)-N-(4-methoxyphenyl)-N, 2, 6-trimethyl-6, 7-dihydro-5 H-cyclopenta [d] pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents. J. Med. Chem., 2011, 54(17), 6151-6155.
60. [60] Gangjee, A., Zhao, Y., Lin, L., Raghavan, S., Roberts, E.G., Risinger, A.L., Hamel, E., Mooberry, S.L. Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance. J. Med. Chem., 2010, 53(22), 8116-8128.
61. [61] Romagnoli, R., Baraldi, P.G., Lopez Cara, C., Kimatrai Salvador, M., Bortolozzi, R., Basso, G., Viola, G., Balzarini, J., Brancale, A., Fu, X.H. One-pot synthesis and biological evaluation of 2-pyrrolidinyl-4-amino-5-(3_, 4_, 5_-trimethoxybenzoyl) thiazole: A unique, highly active antimicrotubule agent. Eur. J. Med. Chem., 2011, 46(12), 6015-6024.
62. [62] Romagnoli, R., Baraldi, P.G., Salvador, M.K., Preti, D., Aghazadeh Tabrizi, M., Brancale, A., Fu, X.H., Li, J., Zhang, S.Z., Hamel, E. Discovery and optimization of a series of 2-aryl-4-amino-5-(3_, 4_, 5_-trimethoxybenzoyl) thiazoles as novel anticancer agents. J. Med. Chem., 2012, 55(11), 5433-5445.
63. [63] Brachet, E., Hamze, A., Peyrat, J.F., Brion, J.D., Alami, M. Pd-catalyzed reaction of sterically hindered hydrazones with aryl halides: synthesis of tetra-substituted olefins related to iso-combretastatin A4. Org. Lett., 2010, 12(18), 4042-4045.
64. [64] Roche, M., Hamze, A., Brion, J.D., Alami, M. Catalytic three-component One-Pot reaction of hydrazones, dihaloarenes, and amines. Org. Lett., 2012, 15(1), 148-151.
65. [65] Kerr, D.J., Hamel, E., Jung, M.K., Flynn, B.L. The concise synthesis of chalcone, indanone and indenone analogues of combretastatin A4. Bioorg. Med. Chem., 2007, 15(9), 3290-3298.
66. [66] Ducki, S., Mackenzie, G., Greedy, B., Armitage, S., Chabert, J.F.D., Bennett, E., Nettles, J., Snyder, J.P., Lawrence, N.J. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 2: Structurebased discovery of alpha-aryl chalcones. Bioorg. Med. Chem., 2009, 17(22), 7711-7722.
67. [67] Arthuis, M., Pontikis, R., Chabot, G.G., Quentin, L., Scherman, D., Florent, J.C. Domino approach to 2-aroyltrimethoxyindoles as novel heterocyclic combretastatin A4 analogues. Eur. J. Med. Chem., 2011, 46(1), 95-100.
68. [68] Lee, H.Y., Chang, J.Y., Nien, C.Y., Kuo, C.C., Shih, K.H., Wu, C.H., Chang, C.Y., Lai, W.Y., Liou, J.P. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2. J. Med. Chem., 2011, 54(24), 8517-8525.
69. [69] Reddy, M.R., Mallireddigari, M.R., Pallela, V.R., Cosenza, S.C., Billa, V.K., Akula, B., Subbaiah, D.V., Bharathi, E.V., Padgaonkar, A., Lv, H. Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents. J. Med. Chem., 2013, 56(13), 5562-5586.
70. [70] Fortin, S., Wei, L., Moreau, E., Lacroix, J., Côté, M.F., Petitclerc, É., Kotra, L.P., Gaudreault, R. Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl) benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4. J. Med. Chem., 2011, 54(13), 4559-4580.